[Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model]. / Molekuliarnye mekhanizmy gipolipidemicheskogo deistviia tsitoprotektora kramizola pri éksperimental'noi dislipidemii.

The tested drug cramizol exhibits lipid-lowering and anti-atherogenic effects. Cramizol reduces blood cholesterol and triglycerides. It also increases HDL and reduces the atherogenic index in rats with the chronic dyslipidemia model induced by a hypercholesterol diet. Cramizol is effective as a hypolipidemic agent and its efficiency is comparable with the reference drug, phenofibrate. Cramizol increases expression of the ApoA1 and ApoC2 genes, and also reduces expression of the Scarb1 gene in rats with experimentally induced hyperlipidemia. These mechanisms could be the basis of its hypolipidemic and anti-atherogenic actions.

[Effects of сramizol on expression of the ApoA1 gene in rats with experimental hyperlipidemia]. / Vliianie kramizola na ékspressiiu gena apolipoproteina A1 (ApoA1) v pecheni krys pri éksperimental'no indutsirovannoi giperlipidemii.

An imidazole derivative cramizol, has lipid-lowering and anti-atherogenic effects. Cramizol reduces blood levels of cholesterol and triglycerides, and also reduces the atherogenic index in animals with acute hyperlipidemia induced by Triton WR-1339. Cramizol and the lipid-lowering drug fenofibrate exhibited similar effectiveness as hypolipidemic agents. Cramizol also restores the expression of the Apoa1 gene in rats with experimentally induced hyperlipidemia to normal values. This may be a basis of its hypolipidemic and anti-atherogenic action.

[Effect of lipid-lowering activity of the natural original enzyme preparation in the experiment]. / Éksperimental'nye dannye o gipolipidemicheskoi aktivnosti otechestvennogo fermentnogo preparata prirodnogo proiskhozhdeniia kholesterinoksidazy.

The experimental study in vivo was aimed at evaluation of hypolipidemic action of the original natural microbial enzyme preparation of cholesterol oxidase (CHO). In preliminary chronic experiments in rats, rabbits, dogs, low toxicity, good tolerability, and anti-atherosclerotic activity of the CHO preparation were established. To assess the effect of CHO under conditions of moderate, nutritional, atherogenic dyslipoproteinemia, experiments were carried out in rats, guinea pigs, and rabbits. It was shown that administration of CHO had the pronounced lipid-lowering effect in models of atherogenic dyslipoproteinemia induced in these animals.

[Hypolipidemic activity of N-cholinergic antagonist Benzohexonium in the experiments ].

Methods: Experiments were carried out on outbred albino male rats (n = 150, 230-250 g). For modeling dislipoproteinemia (DLP) we used 3 models: single intraperitoneal injection of the detergent triton WR-1339; administration of ethanol; maintenance on a special hypercholesterolaemic diet (HD) during 21 days. Animals were divided into four groups: normal control, model group, gemfibrozil (Gfb) group, benzohexonium (Benz) group. Rats received per os benzohexonium (20mg/kg), reference drug gemfibrozil (50 mg/kg). We determined content of total cholesterol (TCh), triglycerides (TG) in samples of blood serum and liver, TCh in aorta. TCh, TG and Ch-HDL were analyzed spectrophotometrically using of standardized methods. Results: Compared with model group the contents of TCh, TG in serum and liver were significantly decreased in model + Benz group, whereas Ch-HDL was raised in rats fed special HD (P<0.05). Calculated index of atherogenity (TCh - Ch-HDL) / (Ch-HDL) showed the positive effect. Conclusion: The results obtained were shown the hypolipidemic activity of N-cholinergic antagonist Benzohexonium (20 mg/kg) lowered the content of lipids in blood, liver, and aorta.

A new activity of N-cholinolytic drug benzohexonium.

We have found that N-cholinolytic drug benzohexonium produces a hypolipidemic effect: it reduces dyslipoproteinemia, fatty infiltration of the liver, and risk of atherosclerotic lesions.

[Hypolipidemic activity of trimethylglycine].

Hypolipidemic properties of a native trimethyl derivative of glycine, trimethylglycine (TMGl), were studied in hyperlipidemic rats and guinea pigs. The administration of TMGl to the hyperlipidemic rats and guinea pigs produced a pronounced hypolipidemic effect. A positive action of TMGl on the lipid profile of blood serum of the experimental animals was observed as manifested by a decrease in the level of cholesterol of low density lipoproteins (LDL) and an increase in the cholesterol level of high density lipoproteins (HDL).

Pharmacological correction of testosterone deficiency during experimental myocardial ischemia.

Experiments on rats with myocardial ischemia modeled by occlusion of the left coronary artery aggravated by alimentary dislipoproteinemia showed that therapy with taurepar (50 mg/kg), a taurine derivative, decreased blood corticosterone concentration and increased the level of endogenous testosterone, which attests to normalization of the compensatory-adaptive and gonadotropic functions of the organism.

[Pharmacological correction of lipid metabolism disturbances using new amide derivatives of taurine].

Taurine derivatives taurepar, tauritman and IEM-1702 exhibit a significant hypolipidemic activity. The most pronounced effect was observed for taurepar, which effectively prevented the experimental dislipoproteinemia in albino rats and guinea pigs.

[Pharmacotherapeutical features of arterial hypertension in patients with diabetes mellitus].

Diabetes mellitus (DM) is often combined with arterial hypertension, which increases the risk of serious complications. The purpose of this review was analysis of the peculiarities of pharmacotherapy with drugs belonging to different groups (ACE inhibitors, calcium channel blockers, alpha- and beta-adrenoblockers, diuretics, angiotensin II blockers, and imidazoline receptor agonists) as a part of combined therapy of compensated DM.

[Anti-atherosclerotic action of mildronate in experiment]. / Antiateroskleroticheskoe deístvie mildronata v éksperimente.

Mildronate is a new antiischemic drug which inhibits biosynthesis of carnitine from butyrobetaine. We studied antiatherosclerotic and antiinflammatory effects of mildronate in guinea-pigs, rats and rabbits. We found a hypolipidemic action of this substance in rats with triton WR-1339 hyperlipidemia. A protective antiatherosclerotic effect of mildronate was observed in rabbits kept on the atherogenic diet for 3 months. Antiinflammatory efficiency of mildronate in rats was demonstrated after injection of bradykinin, carragenine or implantation of a small cotton-wool pad.

[Hypolipidemic effect of sulfated polysaccharides]. / Gipolipidemicheskoe deistvie sul'fatirovannykh polisakharidov.

In experiments on hyperlipidemic rats it was observed the hypolipidemic effect of new sulfated polisaccharides-chitosan, lutelan and krilan sulfates, More pronounced decrease was established in VLDL and increase of HDL after sulfated polysaccharides treatment. The most distinct efficiency exhibites preparation with moledular mass of 20-40 x 10(3) D and the rate of sulfation 9-14%.

[Effectiveness of non-starch polysaccharide crylan in experimental hyperlipidemia]. / Effektivnost' nekrakhmal'nogo polisakharida krilana pri éksperimental'noi giperlipidemii.

In vitro experiments were shown that native ecologically pure non-starch polysaccharide crylan bind the bile acid. Crylan was found to decrease hyperlipidemia induced in rats by means of diet enriched with cholesterol and 6-methylthiouracil. This effect of crylan was more pronounced as compare with the action of native nonspecific enterosorbent polyfepan.

[Hypolipidemic action of phospholipid compounds in experimental animals]. / Gipolipidemicheskoe deistvie fosfolipidnykh kompleksov v éksperimente.

New Russian phospholipid compounds (PLC) made of plants rich in vitamins were tested for effects on induced rat hyperlipidemia in comparison with those of lipostabil (essentiale). Administration of PLC gave rise to a marked hypolipidemic effect, decreased hepatic lipid infiltration and aortic cholesterol. Some novel PLC are much more effective than lipostabil.

[The hypolipidemic activity of natural substances]. / Gipolipidemicheskaia aktivnost' veshchestv prirodnogo proiskhozhdeniia.

Experiments on guinea pigs and rats have revealed that thiazole derivatives of isoflavone has a beneficial effects on disturbed lipid and lipoprotein metabolism. New phospholipid complexes enriched with vitamins have been demonstrated to produce a hypolipidemic effect. Sulfated chitosans decrease lipid infiltration of the liver and elevate serum high density lipoprotein levels in rats.

[The hypolipidemic and antiatherosclerotic action of absorbable and nonabsorbable substances in the intestines]. / Gipolipidemicheskoe i antiateroskleroticheskoe deistvie veshchestv, vsasyvaiushchikhsia i ne vsasyvaiushchikhsia v kishechnike.

Hypolipidemic effect of the polyphenol compound triophen possessing antihypoxic activity was demonstrated in chronic experiments on rabbits. It was also shown that a new derivative of methylxanthine, which does not penetrate the blood--brain barrier, produces a hypolipidemic and antiatherosclerotic effect. Experiments on rats, guinea pigs, and rabbits with induced hyperlipidemia revealed a hypolipidemic effect of new complex compounds which are not absorbed in the intestine--steroid glycosides digitonin and tomatonin immobilized on a polymer. These substances resemble cholesteramine in activity but are distinguished by solubility, low toxicity, and a mechanism of action which is more physiological.